If you could design the perfect bladder cancer risk calculator, what would it include? Dr. Bogdana Schmidt, Dr. Piyush Agarwal, and Dr. Anne Schuckman discuss the next frontier of non-muscle invasive bladder cancer (NMIBC) risk prediction, moving from traditional calculators to

How should MRI and biomarkers work together? Dr. Jason Hafron breaks down where MRI fits into prostate cancer screening, and why guidelines now recommend choosing MRI or a biomarker rather than jumping straight to biopsy. The conversation also explores how variability in MRI

Clinical decisions hinge not only on data, but on how patients interpret risk. This week, @tanray22 and @RuchikaTalwarMD explore how decisional conflict shapes care in urologic oncology and how clinicians can structure clearer, evidence-based conversations @UNCurology #URO278

Optimizing recovery after TURBT means thinking beyond resection. Dr. Sima Porten and Dr. Patrick Hensley join Dr. Vignesh Packiam to explore guiding patients through recovery, balancing medication use, and anticipating complications, especially in those with multiple prior

We’re at #SUO2025! 🙌 Stop by and connect with the BackTable Urology team as we share insights, stories, and new collaborations in GU oncology. Don’t miss our NMIBC Creator Weekend series — available now on all platforms! https://t.co/XTm4NjMTJe

How do you tell inflammation from early recurrence? Dr. Bogdana Schmidt, Dr. Anne Schuckman, and Dr. Piyush Agarwal unpack how seasoned urologists interpret subtle cystoscopic findings to distinguish recurrence from inflammation, and why experience often outpaces risk

When T1 disease involves both the bladder and the ureter, management gets more complex. In the final episode of our NMIBC Creator Weekend series, @spsutkaMD @MarkTysonMD @VigneshPackiam share how they approach these challenging scenarios #URO277 @ferring https://t.co/KgOedJ7zez

Why prostate cancer screening needs an upgrade. PSA changed the game decades ago, but it’s far from perfect. In this clip, Dr. Jason Hafron and Dr. Ruchika Talwar unpack PSA’s limitations, the pitfalls of overdiagnosis, and how genomics and proteomics are paving the way for more

Why prostate cancer screening needs an upgrade. PSA changed the game decades ago, but it’s far from perfect. In this clip, Dr. Jason Hafron and Dr. Ruchika Talwar unpack PSA’s limitations, the pitfalls of overdiagnosis, and how genomics and proteomics are paving the way for more

Can we reduce OR waste without compromising patient care? @SHPatelMD1 joins @RuchikaTalwarMD to discuss evidence-based strategies for greener surgical practice and the implications of sustainability #URO276 @brady_urology https://t.co/S2BoKOs9HG

How do urologists strike the right balance between thorough resection and patient tolerability? Dr. Sima Porten and Dr. Patrick Hensley join Dr. Vignesh Packiam to review key decision points during repeat TURBTs, from when to resect versus biopsy, to ensuring adequate muscle

Headed to SUO? ✈️ @RuchikaTalwarMD shares her top BackTable Urology episodes to queue up for the trip — covering NMIBC, multidisciplinary tumor boards, and GU innovation @UroOnc #SUO2025 https://t.co/3UuzUOnMhQ

What do you do when cytology comes back atypical? Dr. Bogdana Schmidt leads a discussion with Dr. Piyush Agarwal and Dr. Anne Schuckman on how they approach atypical cytology results in non-muscle invasive bladder cancer (NMIBC). From using blue light cystoscopy to integrating

New therapies and biomarkers are opening up paths for patients with recurrent NMIBC. @MarkTysonMD @spsutkaMD and @VigneshPackiam break down how evolving options are reshaping care #URO275 @ferring https://t.co/sn3Lor3BXm

A historic milestone in urology: the first-ever human bladder transplant. @uro_nima joins @RuchikaTalwarMD to discuss how his team completed this operation and what this breakthrough means for the future of urology and transplant medicine Listen here: https://t.co/jTgBgBtzIJ

@jc_hagedorn joins @_backtableUro to break down the real-world essentials of managing Fournier’s Gangrene from recognizing the earliest warning signs to deciding when surgical intervention or transfer is truly urgent. Her discussion sheds light on current best practices and

How do urologists bridge the gap between surgery and survivorship? Dr. Sima Porten and Dr. Patrick Hensley join Dr. Vignesh Packiam to discuss communicating results and next steps after TURBT, guiding patients toward reliable information, and using clear communication to ease

Can biomarkers replace cystoscopy? Here’s what experts think. Dr. Bogdana Schmidt is joined by Dr. Piyush Agarwal and Dr. Anne Schuckman to unpack the practical realities of imaging and biomarkers in non-muscle invasive bladder cancer (NMIBC). The group dives into CTU, MRI, and

BackTable Urology x SUO (@UroOnc) 🎙️ In collaboration with the Society of Urologic Oncology, explore multidisciplinary insights on GU cancer care — from NMIBC to testicular and renal tumors ▶️ Listen now: https://t.co/Qvd7ec6UW3 #SUO2025 #UrologicOncology #Collaboration

@spsutkaMD joins @_backtableUro to explore how emerging biomarkers and AI-driven tools are transforming precision medicine in non-muscle invasive bladder cancer. From reducing reliance on invasive cystoscopies to improving risk stratification, she breaks down where the science